Privacy

1. General
EMD Serono respects the privacy of every individual who visits www.fertilitylifelines.com (the "Web Site"). This Privacy Policy outlines the information EMD Serono will collect and how we will use that information.

2. Personally Identifiable Information
There may be cases where EMD Serono will ask you for personally identifiable information such as your name, mailing address, and email address. For example, we may request personally identifiable information when you participate in a survey, contest, or other service that requires registration or subscription. EMD Serono will not collect any personally identifiable information about you unless you provide it to us voluntarily.

Except as stated in this Privacy Policy, or as otherwise stated at the time personally identifiable information is gathered, we will not provide personally identifiable information to third parties who are not under the direction of EMD Serono.

3. Children
The Web Site is not directed at individuals under eighteen years of age, and EMD Serono does not intend to collect any personally identifiable information from such individuals, unless otherwise stated at the time such information is collected.

4. Information Collected Automatically
EMD Serono may also automatically collect non-personally identifiable information about your use of the Web Site, such as the domain from which you access the Internet (for example, aol.com, if you are connecting from an America Online account), the date and time you access the Web Site, and the Internet address of the website from which you linked directly to our Web Site. This information will not be linked to personally identifiable information. EMD Serono may use this information to analyze and enhance the Web Site, and may aggregate this information and share such aggregated information with business partners, sponsors and other third parties.

5. Links to Other Sites
The Web Site may link to various other web sites. EMD Serono assumes no responsibility for the information practices of sites you are able to access through the Web Site. These links to other sites do not imply affiliation or endorsement of a linked site.

6. Security
The importance of security for all personally identifiable information associated with visitors to the Web Site is of utmost concern to us. Unfortunately, no data transmission over the Internet can be guaranteed to be secure. As a result, EMD Serono cannot ensure or warrant the security of any information you transmit to us, and you do so at your own risk. Once we receive your personally identifiable information, we will take reasonable efforts to ensure its security on our systems.

7. Your Acceptance of These Terms
By using the Web Site, you signify your assent to the EMD Serono Privacy Policy. If you do not agree to this Policy, please do not use the Web Site. Your continued use of the Web Site following the posting of changes to these terms will mean you accept those changes. EMD Serono will, however, use personally identifiable information only in accordance with the version of the Privacy Policy under which the information was collected.

8. Terms and Conditions of Use
Use of the Web Site is governed by the EMD Serono Legal Statement.

Gonal-f® Has Helped Many Couples.

Learn more about this fertility medication.

Say What?

With so many unfamiliar new terms, learning about fertility can feel like you're learning another language. Get the translation by using our glossary.

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

Important Considerations:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Considerations:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading

View the Full Glossary